Skip to main content

Table 3 Factors associated with non-sustained virological response to peginterferon-α and ribavirin treatment in chronic hepatitis C patients

From: Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study

  Groups Univariate analysis Multivariate analysis
Factors SVR Non-SVR Coefficient P-value B Odds ratio 95 % C.I.
Gender (Male/Female) 4234/3740 2426/3080 106.402 <0.001 −0.302 0.739 0.683–0.800
Age (≥65 years/<65 years) 1865/6093 2079/3414 325.742 <0.001 −0.392 0.676 0.618–0.739
History of IFN treatment (naïve/experienced) 6106/1733 3676/1755 172.508 <0.001 −0.407 0.665 0.610–0.726
Genotype (1/2 + 3) 4386/3439 4577/818 1212.744 <0.001 −1.344 0.261 0.238–0.286
Viral load (high/low) 7204/736 5281/182 178.857 <0.001 −1.213 0.297 0.247–0.359
Pre-AST (U/L)* 43 [30–69] (n = 7928) 45 [32–68] (n = 5457)   <0.001    
Pre-ALT (U/L)* 54 [31–93] (n = 7931) 48 [31–75] (n = 5459)   <0.001 0.005 1.005 1.004–1.005
Pre-PLT (x104/μL) 17.0 [14.0–21.0] (n = 7855) 15.0 [12.0–19.0] (n = 5374)   <0.001 0.018 1.019 1.009–1.029
FIB-4 index 2.11 [1.36–3.20] (n = 7833) 2.77 [1.86–4.15] (n = 5357)   <0.001 −0.164 0.849 0.821–0.877
Year of starting treatment – 2008 3062 2327     Reference  
2009 1958 1362 7.949 0.019 −0.085 0.918 0.831–1.015
2010– 2950 1915 −0.095 0.909 0.830–0.997
Region Hokkaido/Tohoku 941 711    −0.288 0.750 0.653–0.861
Kanto 547 316    −0.064 0.938 0.786–1.119
Shin-etsu 361 271    −0.069 0.933 0.765–1.137
Hokuriku 490 354    −0.032 0.969 0.815–1.152
Tokai 557 381 21.777 0.005 −0.069 0.934 0.789–1.105
Kinki 1637 1160    −0.116 0.891 0.790–1.004
Chugoku 1322 920    −0.044 0.957 0.844–1.085
Shikoku 314 257    −0.399 0.671 0.546–0.825
Kyushu 1808 1138     Reference  
  1. The values of pre-AST, pre-ALT, pre-PLT, and FIB-4 index are shown as median [interquartile range]
  2. aSince pre-AST and pre-ALT were closely correlated (r = 0.872; P < 0.001), only pre-ALT was included in multivariate analysis. Significant factors by multivariate analysis are shown in bold. The patients whose treatment outcome could not be determined were excluded from this analysis (n = 576)
  3. ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; C.I., Confidence interval; FIB-4, Fibrosis-4; IFN, Interferon; PLT, Platelets; SVR, Sustained virological response